奥赛康：创新药ASKB589在ESMO年会公布临床研究数据

Core Viewpoint - ASKGENE LIMITED, a subsidiary of Aosaikang (002755), presented promising results for its investigational drug ASKB589 at the ESMO annual meeting, indicating significant potential in treating advanced gastric cancer [1] Group 1: Clinical Research Findings - ASKB589, a monoclonal antibody targeting CLDN18.2, combined with CAPOX (oxaliplatin and capecitabine) and PD-1 inhibitors, showed deep and durable tumor responses in patients with locally advanced, recurrent, or metastatic gastric and gastroesophageal junction adenocarcinoma [1] - The Ib/II phase clinical study demonstrated sustained disease control and clear survival benefits with longer follow-up [1] - These findings support the ongoing pivotal phase III clinical trials of ASKB589 in combination with chemotherapy and PD-1 inhibitors [1]